Shares of Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) were up 2.4% during mid-day trading on Tuesday. The company traded as high as C$0.45 and last traded at C$0.43. Approximately 16,606 shares were traded during mid-day trading, a decline of 80% from the average session volume of 84,140 shares. The stock had previously closed at C$0.42.
Medicenna Therapeutics Stock Performance
The company has a quick ratio of 4.65, a current ratio of 1.25 and a debt-to-equity ratio of 6.22. The company has a 50-day moving average price of C$0.43 and a 200-day moving average price of C$0.56. The firm has a market capitalization of C$39.69 million, a price-to-earnings ratio of -1.95 and a beta of 2.93.
Medicenna Therapeutics Company Profile
Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company’s most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe.
See Also
- Five stocks we like better than Medicenna Therapeutics
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
